Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailErythropoietin and platelet production.
Beguin, Yves ULg

in Haematologica (1999), 84(6), 541-7

BACKGROUND AND OBJECTIVE: Erythropoietin (Epo) is the primary growth factor for the red cell lineage but treatment with recombinant human Epo (rHuEpo) has been shown to increase platelet counts. In ... [more ▼]

BACKGROUND AND OBJECTIVE: Erythropoietin (Epo) is the primary growth factor for the red cell lineage but treatment with recombinant human Epo (rHuEpo) has been shown to increase platelet counts. In several animal species treatment with rHuEpo stimulated platelet production, but platelet counts tended to normalize after 1-2 weeks and large, chronic doses even caused thrombocytopenia. This paper aims to review the evidence about the effects of Epo on megakaryopoiesis. INFORMATION SOURCES: I examined the literature published in journals covered by Medline(R)a concerning the effects of Epo, hypoxia and iron deficiency on megakaryopoiesis and platelets. The reference list of each article was reviewed to try to identify further contributions. STATE OF THE ART: In vivo data have shown that moderate Epo stimulation, i.e. that produced by standard doses of rHuEpo, short-term hypoxia or moderate iron deficiency, causes a moderate elevation of platelet counts, whereas intense Epo stimulation, as produced by high doses of rHuEpo, prolonged hypoxia or severe iron deficiency, causes some degree of thrombocytopenia. In the latter case, there appears to be a diphasic response to Epo, the initial positive response (a stimulation of platelet production) being followed by thrombocytopenia. Contrarily to the thrombocytopenia due to increased platelet destruction induced by other growth factors, Epo-induced thrombocytopenia is the result of an inhibition of platelet production. CONCLUSION AND PERSPECTIVE: Stem-cell competition between erythroid and platelet precursors appears to be the cause of these phenomena in situations of prolonged, intense stimulation by Epo. In vitro data support the existence of a common erythrocytic and megakaryocytic precursor. It remains to be determined whether these effects of rHuEpo are a result of the dose itself or of the magnitude of the erythropoietic effect of that dose. It is not known whether a lower dose given in a patient with decreased marrow function would bring about the same biological effects as those induced by high doses of rHuEpo in the presence of a normal marrow function. Caution should be exercised before using high doses of hematopoietic growth factors. [less ▲]

Detailed reference viewed: 25 (0 ULg)
Peer Reviewed
See detailErythropoietin and the anemia of cancer.
Beguin, Yves ULg

in Acta Clinica Belgica (1996), 51(1), 36-52

The pathogenesis of the anemia of cancer involves the combination of a shortened erythrocyte survival in circulation with the failure of bone marrow to increase red cell production in compensation ... [more ▼]

The pathogenesis of the anemia of cancer involves the combination of a shortened erythrocyte survival in circulation with the failure of bone marrow to increase red cell production in compensation. Inappropriate red cell production is itself related to a conjunction of factors, including impaired availability of reticuloendothelial storage iron, inadequate erythropoietin (Epo) response to anemia, and overproduction of cytokines which are capable of inhibiting erythropoiesis. Many of these cytokines may interfere with erythropoietin production by the kidney. Consequently inadequate serum erythropoietin levels are often encountered in cancer patients, though more frequently in those with solid tumors or multiple myeloma than in those with other hematologic malignancies. There is little evidence supporting a negative impact of chemotherapy, including cisplatin, on erythropoietin production. Rather, chemotherapy usually causes a transient elevation of serum Epo. Red cell transfusions are often administered to cancer patients, possibly resulting, among other deleterious effects, in enhancement of tumor growth. Recombinant human erythropoietin (rHuEpo) has thus been proposed as an alternative. RHuEpo has been shown to be safe and effective in correcting the anemia of cancer and reducing the need for transfusions. The response rate is as good in hematologic malignancies as in solid tumors, but it is extremely poor in those with myelodysplastic syndromes. The effect of rHuEpo does not differ among patients receiving or not receiving chemotherapy, including cisplatin. The probability of response is also similar in patients with adequate or inappropriate erythropoietin production before therapy, although the doses used are usually 2 to 3 times higher than in renal failure patients. [less ▲]

Detailed reference viewed: 21 (2 ULg)
Full Text
Peer Reviewed
See detailErythropoietin improves quality of life--a response.
Bottomley, Andrew; Thomas, Ronald; Van Steen, Kristel ULg et al

in Lancet Oncology (2002), 3(9), 527

Detailed reference viewed: 7 (2 ULg)
Full Text
See detailErythropoietin in surgery
Baudoux, Etienne ULg; Janssens, M.; Beguin, Yves ULg et al

in Proceedings of the 4th Regional Congress of the International Society of Blood Transfusion (1993)

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailErythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial.
JASPERS, Aurélie ULg; Baron, Frédéric ULg; WILLEMS, Evelyne ULg et al

in Belgian Journal of Hematology (2013, January)

Based on the impairment of erythropoietin production after allogeneic hematopoietic cell transplantation (HCT), we previously reported in a phase-2 trial that recombinant human erythropoietin (rhEPO ... [more ▼]

Based on the impairment of erythropoietin production after allogeneic hematopoietic cell transplantation (HCT), we previously reported in a phase-2 trial that recombinant human erythropoietin (rhEPO) therapy was very efficient when started one month after transplantation. We also demonstrated that anemia after nonmyeloabalative (NM) HCT was less sensitive to rhEPO therapy than after conventional allogeneic HCT. This prompted us to confirm these findings in a prospective randomised trial. One hundred and thirty-one patients were randomised (1:1) between no treatment (arm 1) or erythropoietin (Neorecormon) at the dose of 500 U/kg/week (arm 2). Once the target Hb (13g/dL) has been attained, the dose of rhEPO was reduced by half, while it was withheld when Hb was = 14g/dL. Cohort A included 42 patients on day 28 after myeloablative HCT, cohort B 39 patients on day 28 after NMHCT, and cohort C 50 patients on day 0 of NMHCT. Primary endpoints included proportion of complete correctors (i.e. patients reaching Hb = 13g/dL) and median time to achieve Hb correction in each arm. The proportion of complete correctors before day 126 posttransplant was 0% in group 1A vs 52.4% in group 2A, 0% in group 1B vs 69.5% in group 2B and 19.1% in group 1C vs 70.2% in group 2C. Median time to achieve Hb = 13g/dL was not reached in group 1B vs 49 days in group 2B; 363 and 59 days in groups 1A and 1B respectively and 363 and 87 days in groups 3A and 3B respectively (figure 1). Hb evolution in each group is shown in figure 2. Seventyone patients (47/62 in control groups and 24/57 in treated groups, p=0.0003) required red blood cell transfusions. The difference was most pronounced in cohort B. There was no difference in rates of thrombo-embolic events or other complications between the two arms. In conclusion, this is the first trial to demonstrate that EPO therapy hastens erythroid recovery and decreases transfusion requirements when started one month after allogeneic HCT. [less ▲]

Detailed reference viewed: 27 (11 ULg)
Full Text
Peer Reviewed
See detailErythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomized trial
JASPERS, Aurélie ULg; Baron, Frédéric ULg; WILLEMS, Evelyne ULg et al

in Blood (in press)

We conducted a prospective randomized trial to assess hemoglobin (Hb) response to recombinant human erythropoietin (rhEPO) therapy after hematopoietic cell transplantation (HCT). Patients (n=131) were ... [more ▼]

We conducted a prospective randomized trial to assess hemoglobin (Hb) response to recombinant human erythropoietin (rhEPO) therapy after hematopoietic cell transplantation (HCT). Patients (n=131) were randomized (1:1) between no treatment (control arm) or erythropoietin (Neorecormon®) at 500 U/kg/week (EPO arm). Patients were also stratified in 3 cohorts: patients undergoing myeloablative HCT with rhEPO to start on day 28, patients given nonmyeloablative HCT (NMHCT) with rhEPO to start on day 28, and patients also given NMHCT but with rhEPO to start on day 0. The proportion of complete correctors (i.e. achieving Hb ≥ 13 g/dL) before day 126 post-transplant (primary endpoint) was 8.1% in the control arm (median not reached) and 63.1% in the EPO arm (median time 90 days) (p<0.001). Hb levels were higher and transfusions requirements decreased (p<0.001) in the EPO arm, but not during the first month in the nonmyeloablative cohort starting rhEPO on day 0. There was no difference in rates of thrombo-embolic events or other complications between the 2 arms. This is the first randomized trial to demonstrate that rhEPO therapy hastens erythroid recovery and decreases transfusion requirements when started one month after allogeneic HCT. There was no benefit to start rhEPO earlier after NMHCT. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Full Text
See detailErythropoïétine : utilisation diagnostique et thérapeutique
Beguin, Yves ULg; Fillet, Georges ULg

in Revue de l’Association Belge des Technologues de Laboratoire = Tijdschrift van de Belgische Vereniging van Laboratoriumtechnologen (1991), 18(3), 161-168

L'érythropoïétine est une hormone produite par le rein en réponse à une hypoxie rénale et qui stimule l'activité érythropoïétique de la moelle osseuse. Le dosage de l'érythropoïétine sérique, toujours ... [more ▼]

L'érythropoïétine est une hormone produite par le rein en réponse à une hypoxie rénale et qui stimule l'activité érythropoïétique de la moelle osseuse. Le dosage de l'érythropoïétine sérique, toujours interprété en fonction de l'hématocrite circulant, est utile dans le diagnostic différentiel des polyglobulies et dans certains cas particuliers d'anémie. L'utilisation thérapeutique de l'érythropoïétine recombinante a permis de corriger l'anémie de l'insuffisance rénale chronique et est actuellement étudiée dans d'autres indications telles que les anémies inflammatoires. [less ▲]

Detailed reference viewed: 41 (4 ULg)
Peer Reviewed
See detailErythropoietine: utilisation diagnostique et therapeutique.
Beguin, Yves ULg; Fillet, Georges ULg

in Revue Médicale de Liège (1990), 45(6), 261-7

Detailed reference viewed: 24 (4 ULg)
See detailErzählte Kindsbräute bei Heinrich von Kleist, E.T.A. Hoffmann und Theodor Storm
Gerrekens, Louis ULg

in Detering, Heinrich; Fasold, Regina; Stein, Malte (Eds.) Zwischen Mignon und Lulu. Das Phantasma der Kindsbraut in Biedermeier und Realismus (2010)

Detailed reference viewed: 47 (0 ULg)
Full Text
See detailErzählungen über den Zweiten Weltkrieg für Kinder und Jugendliche: Wie ausgewählte Schreibmodi neue Errinerungsorte erschaffen
Delbrassine, Daniel ULg

in Kinder- und Jugendliteraturforschung (2013), 2012-2013

Children novels and picture books: new places of remembrance ?

Detailed reference viewed: 18 (2 ULg)
See detailEs bilde keine Philologen. Christophe Cellarius et sa Dissertation sur l'origine de la langue italienne (1694)
Droixhe, Daniel ULg

in Hirdt, W.; Lieber, M. (Eds.) Kunst und Kommunikation. Betrachtungen zum Medium Sprache in der Romania. Festschrift zum 60. Geburtstag von Richard Baum (1997)

Detailed reference viewed: 21 (3 ULg)
See detailes grottes de la Serra d’Itaqueri, exemple de karsts dans les grès, Brésil
Willems, Luc ULg; Hardt, Rubens; Rodet, Joël

Conference (2012)

Dans l’état de Sao Paulo, au Brésil, de nombreuses cavités sont trouvées dans des grès continentaux du Jurassique affleurant dans le front de la cuesta d’Itaqueri. Ces grottes se développent ... [more ▼]

Dans l’état de Sao Paulo, au Brésil, de nombreuses cavités sont trouvées dans des grès continentaux du Jurassique affleurant dans le front de la cuesta d’Itaqueri. Ces grottes se développent subhorizontalement dans une lithologie compacte et non carbonatée. Elles peuvent s’enfoncer d’une centaine de mètres à dans le massif. Précédemment, plusieurs auteurs ont donné aux différentes failles parcourant les roches un rôle prépondérant dans la genèse des cavités. Deux hypothèses ont été proposées pour leur formation: une dissolution en profondeur, aux nœuds de fracturation et/ou une évacuation mécanique postérieure des résidus d’altération par des écoulements percolant à travers le massif et résurgeant dans le front de cuesta. Pourtant, plusieurs observations telles que l’absence de circulation d'eau à l’intérieur des grottes ou la dislocation de morphologies anciennes par les différentes fractures contredisent ces deux propositions. Les accidents répertoriés au sein des cavités sont datés de 126 Ma et viennent démanteler plus qu’accompagner le développement des systèmes souterrains préexistants. Ces failles permettent de déterminer une karstification initiale des grès antérieure, vraisemblablement en milieu noyé. [less ▲]

Detailed reference viewed: 10 (0 ULg)
Peer Reviewed
See detail*/es-'βɔl‐a‐/ v.intr. « quitter un lieu en s'élevant dans l'air ; se mouvoir dans l'air »
Baiwir, Esther ULg

in Buchi, Eva; Schweickard, Wolfgang (Eds.) Dictionnaire Étymologique Roman (DÉRom) (2014)

Detailed reference viewed: 14 (0 ULg)
See detailEsame ecografico del legamento sopraspinoso nel cavallo
Busoni, Valeria ULg; Denoix, J. M.

in Proceedings del Congresso annuale della Società Italiana di Ippologia (1996)

Detailed reference viewed: 23 (0 ULg)
Peer Reviewed
See detailEsame ecografico dell'apparato podotrocleare del cavallo
Busoni, Valeria ULg; Denoix, J. M.

in Proceedings du Congrès Annuel de la SIVE (1999)

Detailed reference viewed: 21 (1 ULg)
Peer Reviewed
See detailEsame ecografico dello scutum prossimale nel cavallo
Busoni, Valeria ULg; Denoix, J. M.

Poster (1996)

Detailed reference viewed: 43 (1 ULg)
Full Text
Peer Reviewed
See detailESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.
Daemen, Joost; Simoons, Maarten L.; Wijns, William et al

in European heart journal (2009), 30(2), 152-61

Detailed reference viewed: 7 (1 ULg)